Sodium Glucose Co Transporter 2 inhibitors
Showing 1 - 25 of >10,000
Atrial Fibrillation Trial (Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor, Rhythm control and anticoagulation)
Not yet recruiting
- Atrial Fibrillation
- Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
- Rhythm control and anticoagulation
- (no location specified)
Aug 14, 2023
(NIS) on Sodium-glucose Co-transporter-2 Inhibitors Use in
Not yet recruiting
- Diabetes Mellitus, Type 2
- Sodium/glucose cotransporter-2 inhibitors (SGLT2i)
- (no location specified)
May 22, 2023
Acute Pancreatitis in Type 2 Diabetes Mellitus Treated With
Active, not recruiting
- Diabetes Mellitus, Type 2
- empagliflozin
- Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents
-
Ingelheim am Rhein, GermanyBoehringer Ingelheim International GmbH
Aug 19, 2022
Heart Failure With Reduced Ejection Fraction Trial in Chicago (SGLT2i, No SGLT2i)
Recruiting
- Heart Failure With Reduced Ejection Fraction
- SGLT2i
- No SGLT2i
-
Chicago, IllinoisUniversity of Chicago
Nov 11, 2022
SGLT-2 Inhibitors in T2DM and Moderate to Severe Liver Fibrosis
Completed
- Type2diabetes
-
New Delhi, Delhi, IndiaFortis CDOC Hospital
Jul 14, 2023
Lupus Nephritis Trial in Alexandria (Dapagliflozin 10mg Tab orally once daily)
Not yet recruiting
- Lupus Nephritis
- Dapagliflozin 10mg Tab orally once daily
-
Alexandria, EgyptAin Shams University
Oct 27, 2023
Acute Decompensated Heart Failure Trial in Chicago (SGLT2i, No SGLT2i)
Not yet recruiting
- Acute Decompensated Heart Failure
- SGLT2i
- No SGLT2i
-
Chicago, IllinoisUniversity of Chicago
Jun 10, 2022
Chronic Kidney Diseases, Bone Diseases, Metabolic Trial in Mansoura (Dapagliflozin 10mg Tab, Placebo)
Active, not recruiting
- Chronic Kidney Diseases
- Bone Diseases, Metabolic
- Dapagliflozin 10mg Tab
- Placebo
-
Mansoura, Aldakahliya, EgyptUrology and Nephrology center, Mansoura University
Feb 16, 2023
Empagliflozin in Type 2 Diabetes Population With and Without
Not yet recruiting
- Diabetes Mellitus, Type 2
- Empagliflozin
- +3 more
-
Durham, North CarolinaDuke Clinical Research Institute
Aug 8, 2022
Peritoneal Dialysis Complication, End Stage Kidney Disease, Sodium-glucose Co-transporter-2 Inhibitors Trial in Toronto
Not yet recruiting
- Peritoneal Dialysis Complication
- +4 more
- Empagliflozin 25 MG
-
Toronto, Ontario, CanadaToronto General Hospital
Jan 27, 2023
SGLT2-I Use in DFUD: a Delphi Study
Not yet recruiting
- Diabetic Foot Ulcer
- eDelphi method
- (no location specified)
Aug 14, 2023
SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac
Recruiting
- Coronary Artery Disease
- Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
-
Shah Alam, Selangor, MalaysiaInstitute for Clinical Research, National Institutes of Health,
Nov 9, 2023
Acute Kidney Injury, Cardiac Surgery, Sodium-Glucose Transporter 2 Inhibitor Trial in Netherlands (Dapagliflozin 10 MG Oral
Not yet recruiting
- Acute Kidney Injury
- +2 more
- Dapagliflozin 10 MG Oral Tablet [Farxiga]
- Placebo
-
Amsterdam, Netherlands
- +5 more
Oct 18, 2022
Heart Failure, Sleep Disordered Breathing Trial in New York (Dapagliflozin, WatchPat)
Not yet recruiting
- Heart Failure
- Sleep Disordered Breathing
- Dapagliflozin
- WatchPat
-
New York, New YorkVivian and Seymour Milstein Family Heart Center
Mar 8, 2022
Atrial Fibrillation Recurrent, Pulmonary Venous Isolation, Catheter Ablation Trial in Athens (Dapagliflozin, Placebo)
Not yet recruiting
- Atrial Fibrillation Recurrent
- +3 more
- Dapagliflozin
- Placebo
-
Athens, Greece
- +1 more
Jul 26, 2021
Healthy Volunteers Trial run by the NIDDK (Placebo, Canagliflozin)
Completed
- Healthy Volunteers
- Placebo
- Canagliflozin
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 25, 2023
Left Cardiac Catheterization, Percutaneous Coronary Intervention, Acute Kidney Injury Trial in Athens (Dapagliflozin 5mg,
Not yet recruiting
- Left Cardiac Catheterization
- +3 more
- Dapagliflozin 5mg
- Placebo
-
Athens, Greece
- +1 more
Mar 18, 2021
Aortic Valve Stenosis Trial in Strasbourg (Myocardium biopsy)
Not yet recruiting
- Aortic Valve Stenosis
- Myocardium biopsy
-
Strasbourg, FranceHôpitaux Universitaires de Strasbourg
Apr 13, 2023
Metabolic Associated Fatty Liver Disease Trial (dapagliflozin (Forxiga))
Not yet recruiting
- Metabolic Associated Fatty Liver Disease
- dapagliflozin (Forxiga)
- (no location specified)
Mar 13, 2023
Type 2 Diabetes Trial in Hellerup (LY2403021, LY2403021 , Standardised liquid meal)
Completed
- Type 2 Diabetes
- LY2403021
- +6 more
-
Hellerup, DenmarkCenter for Diabetes Research, Gentofte Hospital, Copenhagen Univ
Apr 6, 2020
Diabetes, Type 2, Arterial Hypertension, Body Weight Changes Trial in Torino (SGLT2 inhibitor)
Recruiting
- Diabetes Mellitus, Type 2
- +2 more
- SGLT2 inhibitor
-
Torino, Piemonte, ItalyMauro Maccario
Nov 2, 2020
New Users of SGLT-2 Inhibitors
Completed
- Diabetes Mellitus Type 2
-
Wilmington, Delaware
- +16 more
Feb 17, 2021
![](/image/sponsor/university_of_campania_"luigi_vanvitelli")
Heart Attack, Enlarged Heart Trial in Minneapolis (Dapagliflozin, Placebo)
Recruiting
- Heart Attack
- Enlarged Heart
- Dapagliflozin
- Placebo
-
Minneapolis, MinnesotaMinneapolis Heart Institute Foundation
Aug 4, 2022
Diabetes, Cellular Senescence, Sodium-Glucose Transporter 2 Inhibitors Trial in Seoul (SGLT2 inhibitor, Glimepiride)
Not yet recruiting
- Diabetes Mellitus
- +2 more
- SGLT2 inhibitor
- Glimepiride
-
Seoul, Korea, Republic ofYonsei University College of Medicine
Aug 1, 2023